PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY

妊娠期间抗逆转录病毒治疗的药代动力学特性

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a substudy of P1025 "Perinatal Core Protocol" study and will enroll a total of 125 women, about 4-5 at this site. The purpose of this study is to find the appropriate dose of selected antiretroviral medications for pregnant women as compared to women who are not pregnant. Women who are taking the following antiretroviral medications: Nevirapine 200 mg 2 times a day, Indinavir/Ritonavir 800/100 mg 2 times a day, Kaletra 400/100 mg 2 times a day, Amprenavir 1200 mg 2 times a day, Abacavir 300 mg 2 times a day, will be included in this study. The patient will be seen two times at the GCRC, once during the last three months of pregnancy and again at 6-12 weeks after delivery, for pharmacokinetics. At each visit, a heparin lock will be placed in the patient's arm and at least five, but no more than eight sample (1-2 teaspoons) of blood will be drawn, depending on the medicines the patient is taking. The total amount of blood that will be drawn at each visit will be about 6-9 teaspoons. At the time of delivery, about two teaspoons of blood will be drawn for routine laboratory tests and to measure the amount of aniretroviral medicine in the patient's blood. A blood sample, about two teaspoons, will also be drawn from the umbilical cord that is attached to the placenta. These samples will be in addition to what will be drawn in P1025. The level of HIV antiretroviral medications will be reported back to the patient and her doctor as soon as possible to help decide, in consultation with the patient's doctors, to increase the amount of medicines. The patient has an option of having the amount of medicine measured in the new dose. The benefit of this substudy is to find the correct amount (dose) of antiretroviral medications in pregnancy which will not be done as a standard of care. The risks are associated with blood drawing and the need to be admitted to GCRC for a day (two times) for the pharmacokinetics. Consent will be obtained in the OB clinic during one of the patient's visits.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARGARET A KELLER其他文献

MARGARET A KELLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARGARET A KELLER', 18)}}的其他基金

INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
抗逆转录病毒药物组合 HIV 的深入药代动力学研究
  • 批准号:
    8174501
  • 财政年份:
    2009
  • 资助金额:
    $ 0.74万
  • 项目类别:
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
抗逆转录病毒药物组合的深入药代动力学研究
  • 批准号:
    7952269
  • 财政年份:
    2008
  • 资助金额:
    $ 0.74万
  • 项目类别:
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
HIV 感染青少年大脑的二维 3 Tesla MRS
  • 批准号:
    7494784
  • 财政年份:
    2008
  • 资助金额:
    $ 0.74万
  • 项目类别:
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN VERTICALLY HIV-INFEC
垂直 HIV 感染者形态和代谢异常的患病率
  • 批准号:
    7376075
  • 财政年份:
    2005
  • 资助金额:
    $ 0.74万
  • 项目类别:
MONTHER-INFANT RAPID INTERVENTION AT DELIVERY (MIRIAD)
分娩时的月婴快速干预 (MIRIAD)
  • 批准号:
    7206392
  • 财政年份:
    2004
  • 资助金额:
    $ 0.74万
  • 项目类别:
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN
抗逆转录病毒治疗对艾滋病毒感染儿童身体成分的影响
  • 批准号:
    7206388
  • 财政年份:
    2004
  • 资助金额:
    $ 0.74万
  • 项目类别:
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS. PRO
含蛋白酶抑制剂与含蛋白酶抑制剂的随机试验
  • 批准号:
    7042126
  • 财政年份:
    2003
  • 资助金额:
    $ 0.74万
  • 项目类别:
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN
抗逆转录病毒治疗对艾滋病毒感染儿童身体成分的影响
  • 批准号:
    7042137
  • 财政年份:
    2003
  • 资助金额:
    $ 0.74万
  • 项目类别:
ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF
ACTG382 药代动力学、安全性、耐受性
  • 批准号:
    6416298
  • 财政年份:
    2000
  • 资助金额:
    $ 0.74万
  • 项目类别:
ACTG300 COMBINED ZIDOVUDINE LAMIVUDINE VS BETTER OF DDI MONOTHERAPY V
ACTG300 联合齐多夫定 拉米夫定 VS 更好的 DDI 单疗法 V
  • 批准号:
    6416325
  • 财政年份:
    2000
  • 资助金额:
    $ 0.74万
  • 项目类别:

相似海外基金

RESISTANCE OF HIV-1 TO ANTI-RETROVIRAL AGENTS
HIV-1 对抗逆转录病毒药物的耐药性
  • 批准号:
    3030975
  • 财政年份:
    1993
  • 资助金额:
    $ 0.74万
  • 项目类别:
POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
抗逆转录病毒药物的聚合物递送系统
  • 批准号:
    3489187
  • 财政年份:
    1990
  • 资助金额:
    $ 0.74万
  • 项目类别:
DEVELOPMENTAL VIROLOGY RESEARCH--RESISTANCE TO ANTI-RETROVIRAL AGENTS
发育病毒学研究——抗逆转录病毒药物的耐药性
  • 批准号:
    2335293
  • 财政年份:
  • 资助金额:
    $ 0.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了